RET and non-small cell lung carcinoma: The most common first-line regimens used for patients with non-squamous NSCLC were bevacizumab + carboplatin + pemetrexed (23.9% for the RET+ and 9.8% for the RET- cohort), pembrolizumab + carboplatin + pemetrexed (19.6%, RET+; 14.1% RET-), pemetrexed + carboplatin (13.0% RET+; 16.1% RET-).